GenSpera Obtains Authorization for G-202 Phase II Trial in the United Kingdom

SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy. The Phase II study, which was approved by the United States (US) Food and Drug Administration in July 2012, will be conducted at up to six sites in the US and the UK and will enroll up to 40 patients with chemotherapy-naïve, metastatic castrate-resistant prostate cancer. GenSpera plans to initiate the UK study pending clearance from the Multicentre Research Ethics Committee (MREC).